Skip to main content

Table 4 Secondary outcomes in the ICS cessation and control groups in the 1-year outcome period

From: Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study

 

Total

No. 5230

Control

No. 4184

ICS cessation

No. 1046

Exacerbations

   

 Managed in primary care

0.86 (± 1.33)

0.86 (± 1.32)

0.90 (± 1.35)

 Resulting in A&E attendance

0.09 (± 0.38)

0.09 (± 0.36)

0.11 (± 0.45)

 Total exacerbations

0.96 (± 1.42)

0.94 (± 1.41)

1.01 (± 1.46)

Change in FEV1

   

 Baseline FEV1 (L)

1.39 (± 0.57)

1.36 (± 0.56)

1.49 (± 0.60)

 Outcome FEV1 (L)

1.35 (± 0.58)

1.33 (± 0.58)

1.43 (± 0.60)

 Annualised change in FEV1 (in mL)

− 25.1 (± 248.1)

− 18.8 (± 253.2)

− 48.8 (± 226.4)

 Missing (n (%))

3777 (72.2%)

3035 (72.5%)

742 (70.9%)

CAT score in outcome yeara

 < 10

183 (24.0%)

135 (23.9%)

48 (24.4%)

 ≥ 10

580 (76.0%)

431 (76.1%)

149 (75.6%)

 Mean (SD)

16.6 (± 9.6)

16.8 (± 9.9)

16.2 (± 8.8)

 Missing

4467 (85.4%)

3618 (86.5%)

849 (81.2%)

mMRC dyspnea score in outcome yeara

 0–1

1345 (36.2%)

1072 (35.6%)

273 (38.7%)

 2–4

2371 (63.8%)

1938 (64.4%)

433 (61.3%)

 Mean (SD)

1.9 (± 1.0)

2.0 (± 1.0)

1.9 (± 1.0)

 Missing

1514 (28.9%)

1174 (28.1%)

340 (32.5%)

  1. aFirst score recorded following IPD is used. Values given are mean (SD)